دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Call for emergency action to limit global temperature increases, restore biodiversity, and protect health: Wealthy nations must do much more, much faster
L.Atwoli1A.H.Baqui2T.Benfield3R.Bosurgi4F.Godlee5S.Hancocks6R.Horton7L.Laybourn-Langton8C.A.Monteiro9I.Norman10K.Patrick11N.Praities12M.G.M.Olde Rikkert13E.J.Rubin14P.Sahni15R.Smith16N.Talley17S.Turale18D.Vázquez19
Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care
E.RassyB.Pistilli
Tumor deposits improve staging in colon cancer: what are the next steps?
N.P.M.BrouwerI.D.Nagtegaal
A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning
A.van Ommen-Nijhof1†V.P.Retèl23†M.van den Heuvel4A.Jager5W.H.van Harten26‡G.S.Sonke17‡
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
H.J.Burstein1†G.Curigliano2†B.Thürlimann3W.P.Weber4P.Poortmans5M.M.Regan1H.J.Senn6E.P.Winer1M.Gnant7
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
S.Loi12S.Michiels34S.Adams5S.Loibl678J.Budczies69C.Denkert10R.Salgado111
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
D.Miles1E.Ciruelos23A.Schneeweiss4F.Puglisi56T.Peretz-Yablonski7M.Campone8I.Bondarenko9Z.Nowecki10H.Errihani11S.Paluch-Shimon12‡A.Wardley1314§J.-L.Merot15P.Trask16Y.du Toit17¶C.Pena-Murillo17V.Revelant18D.Klingbiel19T.Bachelot20
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
G.Jerusalem12S.Farah3A.Courtois2J.Chirgwin45S.Aebi67P.Karlsson8P.Neven9E.Hitre10M.P.Graas11E.Simoncini12E.Abdi13C.Kamby14A.Thompson15S.Loibl16J.Gavilá17K.Kuroi18†C.Marth19B.Müller20…M.Colleoni137‡
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆
R.Cohen123Q.Shi4J.Meyers4Z.Jin5M.Svrcek36C.Fuchs78F.Couture9P.Kuebler10K.K.Ciombor11J.Bendell12A.De Jesus-Acosta13P.Kumar14D.Lewis15B.Tan16M.M.Bertagnolli17P.Philip18C.Blanke19E.M.O'Reilly20…J.A.Meyerhardt21
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B.G.M.Hughes12E.Munoz-Couselo3L.Mortier4Å.Bratland5R.Gutzmer67O.Roshdy8R.González Mendoza9J.Schachter10A.Arance11F.Grange12N.Meyer13A.Joshi14S.Billan15P.Zhang16B.Gumuscu16R.F.Swaby16J.-J.Grob17
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
W.He123M.Eriksson3E.Eliasson4F.Grassmann35M.Bäcklund3M.Gabrielson3M.Hammarström3S.Margolin67L.Thorén67Y.Wengström8S.Borgquist910P.Hall36K.Czene3
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
R.Palich1†M.Veyri2†A.Vozy2S.Marot3J.Gligorov4M.-A.Benderra4P.Maingon5L.Morand-Joubert6Z.Adjoutah7A.-G.Marcelin3J.-P.Spano2J.Barrière8
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
P.Guisado-Vasco12L.González-Cortijo23G.D'Errico3A.Serrera-Alvarez4G.Sotres-Fernandez12M.GarcÃa-Coca4J.M.Fernández-Sousa5X.E.Luepke-Estefan6J.A.López-MartÃn7J.M.Jimeno7
Severe COVID-19 in patients with hematological cancers presenting with viremia
J.M.Michot1T.Hueso1N.Ibrahimi2F.Pommeret3C.Willekens1E.Colomba3S.Francis4A.Bayle3P.H.Cournède5M.Merad6S.Foulon2L.Albiges3B.Gachot6F.Barlesi78J.C.Soria7V.Ribrag1F.Griscelli4
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines
N.Colombo12J.A.Ledermann34ESMO Guidelines Committee
Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061
K.Shitara1J.Lunceford2
Suboptimal nutritional support in cancer patients gets excellent results. Reply to the Letter to the Editor: ‘Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial’ by L. Bargetzi et al.
F.Bozzetti
What is optimal nutritional support in acutely ill cancer patients? More may not be better
L.Bargetzi12A.Laviano3Z.Stanga4P.Schuetz12
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
D.J.Slamon1P.Neven2S.Chia3G.Jerusalem4M.De Laurentiis5S.Im6K.Petrakova7G.Valeria Bianchi8M.MartÃn9A.Nusch10G.S.Sonke11L.De la Cruz-Merino12J.T.Beck13Y.Ji14C.Wang15U.Deore14A.Chakravartty14J.P.Zarate14…P.A.Fasching16
Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’: Annals of Oncology 2021; volume 32: 983–993
L.A.Emens1S.Adams2C.H.Barrios3V.Diéras4H.Iwata5S.Loi6H.S.Rugo7A.Schneeweiss8E.P.Winer9S.Patel10V.Henschel11A.Swat12M.Kaul13L.Molinero14S.Patel15S.Y.Chui10P.Schmid16
Corrigendum to ‘P-195 Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients’: Ann Oncol 32 suppl. 3; 2021: S166
J.Nshizirungu1S.Bennis1I.Mellouki2M.Sekal3D.Benajah4N.Lahmidani4H.El Bouhaddouti5K.Majdoub5S.Ibrahimi6S.Celeiro7M.Viana-Pereira7R.Reis8
Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’: Annals of Oncology 2021; volume 32: 696-697
R.Gutzmer1V.Sibaud2J.C.Hassel3
